Wolfe Research Reiterates “Peer Perform” Rating for Centessa Pharmaceuticals (NASDAQ:CNTA)

Centessa Pharmaceuticals (NASDAQ:CNTA)‘s stock had its “peer perform” rating reiterated by equities researchers at Wolfe Research in a research report issued to clients and investors on Tuesday,Benzinga reports.

Other research analysts also recently issued research reports about the company. Truist Financial raised their price objective on Centessa Pharmaceuticals from $33.00 to $38.00 and gave the stock a “buy” rating in a research note on Thursday, January 29th. Needham & Company LLC reiterated a “hold” rating on shares of Centessa Pharmaceuticals in a research note on Tuesday. Chardan Capital reissued a “buy” rating and issued a $30.00 target price on shares of Centessa Pharmaceuticals in a report on Friday, January 2nd. Oppenheimer raised their target price on shares of Centessa Pharmaceuticals from $40.00 to $62.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Centessa Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $40.00.

Centessa Pharmaceuticals Stock Performance

NASDAQ CNTA traded up $12.36 on Tuesday, hitting $39.94. 25,443,749 shares of the company traded hands, compared to its average volume of 1,818,023. The company has a market capitalization of $5.83 billion, a price-to-earnings ratio of -21.84 and a beta of 1.54. The company has a current ratio of 10.56, a quick ratio of 10.57 and a debt-to-equity ratio of 0.36. The business’s 50 day moving average price is $25.96 and its 200-day moving average price is $25.12. Centessa Pharmaceuticals has a 52-week low of $9.60 and a 52-week high of $40.26.

Insider Transactions at Centessa Pharmaceuticals

In other news, insider Gregory M. Weinhoff sold 73,196 shares of the company’s stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $26.33, for a total value of $1,927,250.68. Following the completion of the transaction, the insider owned 65,925 shares of the company’s stock, valued at $1,735,805.25. This represents a 52.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Iqbal J. Hussain sold 38,951 shares of the stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $25.15, for a total value of $979,617.65. Following the sale, the insider owned 57,645 shares of the company’s stock, valued at $1,449,771.75. This represents a 40.32% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 349,073 shares of company stock valued at $9,429,412 over the last 90 days. Company insiders own 7.09% of the company’s stock.

Institutional Investors Weigh In On Centessa Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in CNTA. Millennium Management LLC lifted its holdings in shares of Centessa Pharmaceuticals by 52.9% in the first quarter. Millennium Management LLC now owns 609,188 shares of the company’s stock worth $8,760,000 after buying an additional 210,737 shares in the last quarter. Jane Street Group LLC purchased a new position in Centessa Pharmaceuticals during the first quarter valued at $2,176,000. Geode Capital Management LLC grew its stake in Centessa Pharmaceuticals by 44.7% during the second quarter. Geode Capital Management LLC now owns 87,435 shares of the company’s stock valued at $1,149,000 after acquiring an additional 26,994 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Centessa Pharmaceuticals by 155.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 428,434 shares of the company’s stock valued at $5,630,000 after acquiring an additional 260,702 shares during the last quarter. Finally, Legal & General Group Plc increased its holdings in Centessa Pharmaceuticals by 29.2% in the 2nd quarter. Legal & General Group Plc now owns 98,256 shares of the company’s stock valued at $1,291,000 after acquiring an additional 22,205 shares during the last quarter. 82.01% of the stock is owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals News Roundup

Here are the key news stories impacting Centessa Pharmaceuticals this week:

• Positive Sentiment: Eli Lilly agreed to buy Centessa in a multi‑billion dollar deal that values the company at an initial ~$6.3 billion with potential to rise (reports cite up to $7.8B including milestones). The acquisition validates Centessa’s sleep‑wake OX2R agonist program and is the primary driver of the share rise. Read More. Read More.
• Positive Sentiment: Centessa’s pipeline and strategic fit: Lilly emphasized Centessa’s OX2R agonists as potentially best‑in‑class candidates to treat excessive daytime sleepiness and narcolepsy, which supports premium pricing for the deal and long‑term value for shareholders. Read More.
• Positive Sentiment: Unusual options activity: Large call buying was reported (nearly a 5x jump vs. typical call volume), consistent with bullish positioning tied to the takeover news and expectations of an offer-related premium. (Entry: unusual options trading reported 3/31)
• Neutral Sentiment: Analyst stance: Needham reaffirmed a “hold” on the stock — a sign analysts are waiting for deal closing and final terms rather than changing near‑term views immediately. Read More.
• Neutral Sentiment: Trading mechanics: Volume surged well above average and the stock is trading far above its 50‑ and 200‑day moving averages, reflecting deal news and momentum rather than company operational updates. (Background trading data)
• Negative Sentiment: Potential shareholder challenge / fairness probe: Halper Sadeh LLC is investigating whether Centessa’s shareholders are receiving a fair price, which could lead to legal scrutiny or demands for a higher bid and introduce execution risk or delay. Read More.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.